Mild Course of SARS-CoV-2 Infection in a Liver Transplant Recipient Undergoing Plasma Exchange and Defibrotide for Acute Graft Rejection
Authors:
- 26 January 2021
- journal article
- letter
- Published by Wolters Kluwer Health in Transplantation
- Vol. 105 (2) , e22-e24
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry studyThe Lancet Gastroenterology & Hepatology, 2020
- The coagulopathy, endotheliopathy, and vasculitis of COVID-19Inflammation Research, 2020
- Detection and quantification of SARS-CoV-2 by droplet digital PCR in real-time PCR negative nasopharyngeal swabs from suspected COVID-19 patientsPLOS ONE, 2020
- Plasma Exchange: An Effective Rescue Therapy in Critically Ill Patients With Coronavirus Disease 2019 InfectionCritical Care Medicine, 2020
- Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 VirusCell, 2020
- Antibody seroconversion in asymptomatic and symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)Clinical & Translational Immunology, 2020
- What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romanceBlood, 2016
- The mechanisms of action of plasma exchangeBritish Journal of Haematology, 2013
- Plasma exchange therapy for thrombotic microangiopathiesOrganogenesis, 2011
- Hepatic veno-occlusive disease due to tacrolimus in a single-lung transplant patientEuropean Respiratory Journal, 2006